TSHA

Taysha Gene Therapies, Inc.

Insider Trades

NameValueActionPriceCurrent Price
Nagendran SukumarDirector, Officer: President And Head Of R&D
$892k200k shares
SellApr 10, 2026
$4.46
--
Alam KamranCHIEF FINANCIAL OFFICER
$7.5k1.7k shares
SellFeb 4, 2026
$4.52
--
Nolan Sean P.Director, Officer: Chief Executive Officer
$190k41.3k shares
SellJan 26, 2026
$4.61
--
Nagendran SukumarDirector, Officer: President And Head Of R&D
$124k26.9k shares
SellJan 26, 2026
$4.61
--
Alam KamranCHIEF FINANCIAL OFFICER
$110k23.8k shares
SellJan 26, 2026
$4.61
--
Nolan Sean P.Director, Officer: Chief Executive Officer
$650k136.8k shares
SellJan 23, 2026
$4.75
--

News

globenewswire.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)globenewswire.comJun 5globenewswire.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)globenewswire.comJun 5seekingalpha.comTaysha Gene Therapies: Shortened Timeline Increases The Potentialseekingalpha.comJun 1seekingalpha.comTaysha Gene Therapies, Inc. (TSHA) Q1 2026 Earnings Call Transcriptseekingalpha.comMay 6globenewswire.comTaysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Updateglobenewswire.comMay 6